Page 101 - 《中国药房》2022年12期

mia-free survival in B-cell acute lymphoblastic leukemia [25] LOCATELLI F，WHITLOCK J A，PETERS C，et al. Blina-
[J]. Expert Rev Hematol，2017，10（12）：1057-1067. tumomab versus historical standard therapy in pediatric
[13] BRAIG F，BRANDT A，GOEBELER M，et al. Resistance patients with relapsed/refractory Ph-negative B-cell pre-
to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia cursor acute lymphoblastic leukemia[J]. Leukemia，2020，
may be mediated by disrupted CD19 membrane traf- 34（9）：2473-2478.
ficking[J]. Blood，2017，129（1）：100-104. [26] RAMBALDI A，RIBERA J M，KANTARJIAN H M，et al.
[14] CONDE-ROYO D，JUÁREZ-SALCEDO L M，DALIA S. Blinatumomab compared with standard of care for the
Management of adverse effects of new monoclonal anti- treatment of adult patients with relapsed/refractory
body treatments in acute lymphoblastic leukemia[J]. Drugs Philadelphia chromosome-positive B-precursor acute
Context，2020，9：2020-2027-2. lymphoblastic leukemia[J]. Cancer，2020，126（2）：304-
[15] BENNETT J M，CATOVSKY D，DANIEL M T，et al. Pro- 310.
posals for the classification of the acute leukaemias： [27] WU J J，FU J P，ZHANG M Z，et al. Blinatumomab：a
French-American-British（FAB）co-operative group[J]. Br bispecific T cell engager（BiTE）antibody against CD19/
J Haematol，1976，33（4）：451-458. CD3 for refractory acute lymphoid leukemia[J]. J Hematol
[16] LOCATELLI F，ZUGMAIER G，RIZZARI C，et al. Effect Oncol，2015，8：104.
of blinatumomab vs chemotherapy on event-free survival [28] SUN Z C，REN Z H，YANG K T，et al. A next-generation
among children with high-risk first-relapse B-cell acute tumor-targeting IL-2 preferentially promotes tumor-in-
lymphoblastic leukemia：a randomized clinical trial[J]. filtrating CD8 T-cell response and effective tumor control
+
JAMA，2021，325（9）：843-854. [J]. Nat Commun，2019，10（1）：3874.
[17] HHS，NIH，NCI. Common terminology criteria for adverse [29] STEIN A S，SCHILLER G，BENJAMIN R，et al. Neu-
events（CTCAE）version 4.0[EB/OL].（2010-06-14）[2021- rologic adverse events in patients with relapsed/refractory
11-20]. http：//evs.nci.nih.gov/ftp1/CTCAE/About.html. acute lymphoblastic leukemia treated with blinatumomab：
[18] HIGGINS J，GREEN S. Cochrane handbook for systematic management and mitigating factors[J]. Ann Hematol，
reviews of interventions，version 5.1.0[EB/OL].（2011-03- 2019，98（1）：159-167.
20）[2021-11-20]. https：// handbook-5-1.cochrane.org/. [30] TURTLE C J，HANAFI L A，BERGER C，et al. CD19
[19] STANG A. Critical evaluation of the Newcastle-Ottawa CAR-T cells of defined CD4 ：CD8 composition in adult
+
+
scale for the assessment of the quality of nonrandomized B cell ALL patients[J]. J Clin Invest，2016，126（6）：2123-
studies in meta-analyses[J]. Eur J Epidemiol，2010，25（9）： 2138.
603-605. [31] GIEBEL S，THOMAS X，HALLBOOK H，et al. The
[20] GUYATT G H，OXMAN A D，VIST G E，et al. GRADE： prophylactic use of granulocyte-colony stimulating factor
an emerging consensus on rating quality of evidence and during remission induction is associated with increased
strength of recommendations[J]. BMJ，2008，336（7650）： leukaemia-free survival of adults with acute lympho-
924-926. blastic leukaemia：a joint analysis of five randomised
[21] BROWN P A，JI L Y，XU X X，et al. Effect of postrein- trials on behalf of the EWALL[J]. Eur J Cancer，2012，48
duction therapy consolidation with blinatumomab vs （3）：360-367.
chemotherapy on disease-free survival in children，ado- [32] MARTINELLI G，BOISSEL N，CHEVALLIER P，et al.
lescents，and young adults with first relapse of B-cell Complete hematologic and molecular response in adult
acute lymphoblastic leukemia：a randomized clinical patients with relapsed/refractory Philadelphia chromo-
trial[J]. JAMA，2021，325（9）：833-842. somepositive B-precursor acute lymphoblastic leukemia
[22] AMPATZIDOU M，KATTAMIS A，BAKA M，et al. Insights following treatment with blinatumomab：results from a
from the Greek experience of the use of blinatumomab in phase Ⅱ，single-arm，multicenter study[J]. J Clin Oncol，
pediatric relapsed and refractory acute lymphoblastic 2017，35（16）：1795-1802.
leukemia patients[J]. Neoplasma，2020，67（6）：1424-1430. [33] MIKULSKA M，LANINI S，GUDIOL C，et al. ESCMID
[23] GÖKBUGET N，KELSH M，CHIA V，et al. Blinatumomab Study Group for Infections in Compromised Hosts
vs historical standard therapy of adult relapsed/refractory （ESGICH）consensus document on the safety of targeted
acute lymphoblastic leukemia[J]. Blood Cancer J，2016，6 and biological therapies：an infectious diseases perspective
（9）：e473. （agents targeting lymphoid cells surface antigens[Ⅰ]：
[24] GÖKBUGET N，DOMBRET H，GIEBEL S，et al. Blinatu- CD19，CD20 and CD52）[J]. Clin Microbiol Infect，2018，
momab vs historic standard-of-care treatment for minimal 24 Suppl 2：S71-S82.
residual disease in adults with B-cell precursor acute （收稿日期：2022-01-03 修回日期：2022-05-04）
lymphoblastic leukaemia[J]. Eur J Haematol，2020，104 （编辑：陈 宏）
（4）：299-309.

中国药房 2022年第33卷第12期 China Pharmacy 2022 Vol. 33 No. 12 ·1499 ·